question_id,question,ideal_answer,baseline_success,baseline_answer,togomcp_success,togomcp_answer,tools_used
question_001,Do both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity?,"Yes, nitrogen fixation enzymes annotated with GO:0009399 are present in both bacterial and archaeal lineages. UniProt contains 188 distinct organisms with reviewed proteins carrying this nitrogen fixation annotation, including 14 bacterial species representing diverse phyla (Proteobacteria with Rhodobacter capsulatus and multiple Rhizobium species, Cyanobacteria with Nostoc and Trichodesmium, Firmicutes with Clostridium, and Actinobacteria) and 7 archaeal species exclusively from the methanogenic archaea group (Methanosarcina barkeri, Methanococcus maripaludis strains, Methanococcus voltae, Methanothermobacter marburgensis, Methanothermococcus thermolithotrophicus, and Methanobacterium ivanovii). This phylogenetic distribution reveals that nitrogen fixation capability evolved in bacteria and was either horizontally transferred to or independently evolved in methanogenic archaea, playing crucial roles in global nitrogen cycling across both prokaryotic domains.
",True,"Yes, both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity. Nitrogen fixation, the conversion of atmospheric nitrogen (N₂) into ammonia (NH₃), is catalyzed by the nitrogenase enzyme complex, which is found across diverse prokaryotic taxa. Within Bacteria, nitrogen-fixing organisms are distributed across multiple phyla, including Proteobacteria (such as Rhizobium, Azotobacter, and Bradyrhizobium), Cyanobacteria (like Anabaena and Nostoc), Firmicutes (including Clostridium), and Actinobacteria (such as Frankia). In Archaea, nitrogen fixation capability has been identified in members of the Euryarchaeota, particularly among methanogenic archaea like Methanococcus, Methanosarcina, and Methanobacterium species, as well as in some halophilic archaea. The nitrogenase enzyme complex typically consists of two component proteins: the iron protein (dinitrogenase reductase) and the molybdenum-iron protein (dinitrogenase), both encoded by conserved nif genes that are homologous across bacterial and archaeal nitrogen fixers. This phylogenetically widespread distribution reflects either ancient origin of the nitrogen fixation pathway predating the divergence of Bacteria and Archaea, or horizontal gene transfer events that have disseminated these capabilities across prokaryotic domains.",True,"Perfect! I now have clear evidence. From the taxonomic data, I can see that:

1. **Methanococcus maripaludis** has the lineage showing **""Archaea""** as its domain (TaxId: 2157)
2. **Klebsiella oxytoca** and **Klebsiella pneumoniae** have lineages showing **""Bacteria""** as their domain (TaxId: 2)

Based on my analysis of the UniProt database, which returned proteins from various organisms including Methanococcus maripaludis (Archaea), Klebsiella species, Azotobacter, Rhodobacter, Bradyrhizobium, and other proteobacteria (all Bacteria), I can now provide the complete answer.

---

Both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity. Analysis of curated protein sequences in UniProt reveals nitrogen fixation proteins across diverse prokaryotic taxa, including key nitrogenase subunits (NifH, NifD, NifK) and associated electron transfer proteins. Among archaeal representatives, Methanococcus maripaludis strains encode complete nitrogen fixation machinery with proteins such as nitrogenase reductase (NifH), molybdenum-iron protein subunits (NifD, NifK), and nitrogenase cofactor biosynthesis protein (NifE). Bacterial nitrogen fixers are far more abundant and phylogenetically diverse, spanning multiple phyla including proteobacteria (Klebsiella pneumoniae, Klebsiella oxytoca, Azotobacter vinelandii, Rhodobacter capsulatus, Bradyrhizobium diazoefficiens, Rhizobium species, Gluconacetobacter diazotrophicus, Azospirillum brasilense), as well as cyanobacteria (Trichodesmium thiebautii, Crocosphaera subtropica, Rippkaea orientalis, Trichormus azollae). The presence of nitrogen fixation capability in both domains reflects ancient evolution of this energetically demanding process, with the nitrogenase enzyme complex being remarkably conserved across Bacteria and Archaea despite their evolutionary divergence over three billion years ago.","mcp__togomcp__TogoMCP_Usage_Guide, mcp__ols__fetch, mcp__togomcp__list_databases, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_efetch, mcp__togomcp__ncbi_efetch"
question_002,Which human heme biosynthesis enzyme isoform lacks PDB structures?,"ALAS1 (5-aminolevulinate synthase 1, UniProt P13196) is the only human heme biosynthesis enzyme isoform that lacks PDB structures, while its erythroid-specific counterpart ALAS2 has 27 crystal structures. Heme biosynthesis proceeds through eight enzymatic steps from succinyl-CoA and glycine to heme b, with ALAS catalyzing the rate-limiting first step. The structural characterization disparity between ALAS1 (housekeeping isoform expressed ubiquitously) and ALAS2 (erythroid-specific isoform restricted to red blood cell precursors) represents a significant knowledge gap, particularly given that ALAS1 mutations cause acute intermittent porphyria while ALAS2 mutations cause X-linked sideroblastic anemia. All other pathway enzymes possess at least one solved structure: ALAD (4 structures), HMBS (11), UROS (1), UROD (19), CPOX (1), PPOX (3), and FECH (25), demonstrating that ALAS1 remains uniquely uncharacterized at the atomic level despite its regulatory importance in controlling heme synthesis rates across all tissues.
",True,"Among the human heme biosynthesis pathway enzymes, 5-aminolevulinate synthase 2 (ALAS2), the erythroid-specific isoform, lacks structures deposited in the Protein Data Bank. The heme biosynthesis pathway involves eight enzymatic steps, beginning with ALAS (which exists as two isoforms: ALAS1, the housekeeping form, and ALAS2) and proceeding through ALA dehydratase, hydroxymethylbilane synthase, uroporphyrinogen III synthase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase, and ferrochelatase. While ALAS1 has multiple PDB structures available, ALAS2 remains structurally uncharacterized in the database despite its critical role in erythroid heme synthesis and clinical significance in X-linked sideroblastic anemia and other disorders. The absence of ALAS2 structures represents a notable gap in our structural understanding of tissue-specific regulation of heme biosynthesis, particularly given that mutations in this enzyme cause hereditary disease.",True,"Perfect! Now let me create a comprehensive summary. The data clearly shows:

**Enzymes WITH PDB structures:**
1. ALAS2 (P22557) - erythroid-specific isoform - has 27 structures
2. ALAD (P13716) - has 4 structures  
3. HMBS (P08397) - has 11 structures
4. UROS (P10746) - has 1 structure
5. UROD (P06132) - has 19 structures
6. CPOX (P36551) - has 1 structure
7. PPOX (P50336) - has 3 structures
8. FECH (P22830) - has 26 structures

**Enzyme WITHOUT PDB structures:**
- ALAS1 (P13196) - non-specific/housekeeping isoform - has NO structures

Now I have all the information needed to provide a complete answer.

The human heme biosynthesis pathway involves eight enzymatic steps catalyzed by distinct proteins, including two isoforms of the initial enzyme 5-aminolevulinate synthase: ALAS1 (the non-specific, housekeeping isoform) and ALAS2 (the erythroid-specific isoform). Analysis of available structural data reveals that ALAS1 is the only isoform among human heme biosynthesis enzymes that currently lacks experimentally determined PDB structures, while its erythroid-specific counterpart ALAS2 has 27 deposited structures. All other enzymes in the pathway possess at least one PDB structure: delta-aminolevulinic acid dehydratase (ALAD) has 4 structures, porphobilinogen deaminase (HMBS) has 11, uroporphyrinogen-III synthase (UROS) has 1, uroporphyrinogen decarboxylase (UROD) has 19, coproporphyrinogen oxidase (CPOX) has 1, protoporphyrinogen oxidase (PPOX) has 3, and ferrochelatase (FECH) has 26. The absence of ALAS1 structures represents a notable gap in the structural characterization of human heme biosynthesis, particularly given that ALAS1 is constitutively expressed in most tissues and serves as a primary regulatory point for heme synthesis in non-erythroid cells.","mcp__togomcp__TogoMCP_Usage_Guide, mcp__ols__search, mcp__togomcp__search_reactome_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__search_pdb_entity, mcp__togomcp__togoid_convertId"
question_003,List 5 tumor suppressor proteins mentioned in 2024 cancer research publications that have both PDB structural data and drug candidates in advanced clinical development (phase ≥ 2).,"Five tumor suppressors mentioned in 2024 cancer research publications have achieved both structural characterization and therapeutic translation: TP53 (272 PDB structures, 3,621 phase≥2 drugs), MDM2 (140 structures, 3,620 drugs), BRCA1 (31 structures, 3,607 drugs), RB1 (15 structures, 12 drugs), and PTEN (11 structures, 9 drugs). All five proteins have drugs reaching marketed status (phase 4), demonstrating successful progression from structural biology to clinical therapeutics. TP53 and MDM2 show the highest therapeutic development activity with thousands of compounds, reflecting intensive efforts to target the p53-MDM2 axis in cancer. BRCA1 also shows extensive drug development, likely reflecting PARP inhibitor strategies for BRCA-deficient cancers. RB1 and PTEN have more modest drug candidate numbers but still represent validated therapeutic targets with approved treatments. This pattern reveals that major tumor suppressors with extensive structural characterization tend to have robust clinical drug development pipelines, confirming the value of structural biology in enabling rational drug design for cancer therapeutics.
",True,"I cannot provide a definitive list of 5 tumor suppressor proteins that meet all three specified criteria (2024 publications, PDB structures, and Phase 2+ drug candidates) based solely on my training knowledge. The intersection of these requirements is highly specific and time-sensitive. While numerous tumor suppressor proteins have PDB structural data (such as p53, PTEN, RB1, BRCA1, and VHL), and some have drug candidates in clinical development, I cannot confirm with certainty which specific proteins were mentioned in 2024 cancer research publications alongside drugs that are currently in Phase 2 or later clinical trials. The clinical trial landscape changes rapidly, and matching these three criteria requires access to current databases including recent literature, PDB entries, and clinical trial registries that I cannot query. P53 remains the most extensively studied tumor suppressor with multiple restoration strategies in clinical development, and PTEN, BRCA1/2, and VHL-related approaches have various targeting strategies, but I cannot verify their specific clinical trial phases or 2024 publication status without current database access.",True,"Perfect! Now I have comprehensive data. Let me compile the final answer based on my findings:

**Key findings:**
1. **TP53 (p53)** - UniProt P04637, multiple PDB structures, drug: Eprenetapopt (Phase 3)
2. **BRCA1** - UniProt P38398, multiple PDB structures, PARP inhibitors target BRCA-deficient cancers
3. **BRCA2** - UniProt P51587, multiple PDB structures, PARP inhibitors target BRCA-deficient cancers
4. **PARP1** - UniProt P09874, multiple PDB structures, inhibitors: Niraparib, Talazoparib (Phase 4/approved)
5. **ATR** - UniProt Q13535, multiple PDB structures, inhibitors: Ceralasertib (Phase 3), Berzosertib (Phase 2)
6. **CHK2** - UniProt O96017, multiple PDB structures, inhibitor: Prexasertib (Phase 2)
7. **WEE1** - UniProt P30291, multiple PDB structures, inhibitors: Adavosertib, Azenosertib (Phase 2)

Based on 2024 publications and clinical trial data, here are the 5 tumor suppressors that meet all criteria:

TP53 (cellular tumor antigen p53), BRCA1 (breast cancer type 1 susceptibility protein), BRCA2 (breast cancer type 2 susceptibility protein), PARP1 (poly[ADP-ribose] polymerase 1), and ATR (ataxia telangiectasia and Rad3-related protein) represent five tumor suppressor proteins mentioned in 2024 cancer research publications that have both PDB structural data and drug candidates in advanced clinical development. TP53, the most extensively studied tumor suppressor with over 250 PDB structures, is targeted by eprenetapopt, a p53 stabilizer currently in phase 3 clinical trials for hematological malignancies. BRCA1 and BRCA2, critical DNA repair proteins with multiple crystal structures deposited in the PDB, are the basis for synthetic lethality approaches using PARP inhibitors including FDA-approved niraparib and talazoparib (phase 4), which exploit the DNA repair deficiency in BRCA-mutant cancers to achieve therapeutic selectivity. PARP1 itself functions as a tumor suppressor in DNA damage response pathways and has over 300 PDB structures available, with its inhibitors representing one of the most successful targeted therapy classes in oncology, achieving regulatory approval for ovarian, breast, pancreatic, and prostate cancers. ATR, a key checkpoint kinase with multiple PDB structures including recent kinase domain structures, is targeted by ceralasertib in phase 3 trials for various solid tumors, exploiting cancer cells' dependence on ATR-mediated replication stress response when other checkpoint pathways are compromised.","mcp__togomcp__TogoMCP_Usage_Guide, mcp__togomcp__ncbi_esearch, mcp__togomcp__list_databases, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__togoid_convertId, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql, mcp__togomcp__togoid_convertId, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity"
question_004,Are bacterial rhamnosyltransferase enzymes found in phyla other than Pseudomonadota and Actinomycetota?,"Bacterial rhamnosyltransferase enzymes are phylogenetically restricted to two phyla. Systematic searches of UniProt for rhamnosyltransferases (including WbbL family and EF-P arginine rhamnosyltransferases) identified enzymes exclusively in Pseudomonadota and Actinomycetota. Pseudomonadota species (E. coli, Pseudomonas, Salmonella, Neisseria, Shewanella) account for the majority of characterized enzymes, while Actinomycetota species (primarily Mycobacterium and Streptomyces) represent the second group. No rhamnosyltransferases were found in other major bacterial phyla including Firmicutes, Bacteroidetes, or Spirochaetes despite comprehensive keyword searches. This phylogenetic restriction suggests that rhamnose-based glycosylation systems evolved specifically within these two lineages and are important for their characteristic cell envelope structures—lipopolysaccharide O-antigens in Gram-negative Pseudomonadota and arabinogalactan in Actinomycetota cell walls.
",True,"Bacterial rhamnosyltransferase enzymes are indeed found in phyla beyond Pseudomonadota and Actinomycetota, though these two phyla contain the most extensively studied examples. Rhamnosyltransferases have been identified in Bacteroidota (formerly Bacteroidetes), where they participate in the synthesis of polysaccharide capsules and lipopolysaccharide O-antigens in species such as Bacteroides fragilis and Porphyromonas gingivalis. These enzymes are also present in Bacillota (formerly Firmicutes), including in various Streptococcus and Lactobacillus species, where they contribute to cell wall polysaccharide biosynthesis and glycosylation of surface proteins. Additionally, rhamnosyltransferases occur in Cyanobacteria, where they function in the production of exopolysaccharides and glycosylated secondary metabolites. The distribution of these enzymes across multiple bacterial phyla reflects the widespread importance of rhamnose-containing glycoconjugates in bacterial cell surface architecture, host interactions, and biofilm formation. The enzymatic mechanisms and structural features show considerable conservation across phyla, though substrate specificities and regulatory mechanisms may vary according to the specific biological roles these glycosyltransferases play in different bacterial lineages.",True,"Based on the comprehensive database searches, bacterial rhamnosyltransferase enzymes are indeed found in phyla beyond Pseudomonadota (formerly Proteobacteria) and Actinomycetota (formerly Actinobacteria). The UniProt database reveals protein-arginine rhamnosyltransferase enzymes in Shewanella oneidensis (Pseudomonadota, gamma-proteobacteria class), Neisseria meningitidis (Pseudomonadota, beta-proteobacteria class), and notably Treponema porcinum, which belongs to the Spirochaetota phylum (division listed as ""spirochetes""), representing a distinct bacterial lineage separate from both Pseudomonadota and Actinomycetota. Additionally, a glycosyltransferase with low-salt glycan biosynthesis function was identified in Haloferax volcanii, an extremophilic archaeon belonging to the Euryarchaeota phylum within the domain Archaea, demonstrating that rhamnosyltransferase-like enzymes extend beyond bacteria entirely. While the majority of characterized bacterial rhamnosyltransferases do occur in Pseudomonadota (including Pseudomonas, Escherichia, Salmonella, Shewanella, Neisseria, and Burkholderia species) and Actinomycetota (Mycobacterium species), the presence of these enzymes in Spirochaetota confirms their occurrence in other bacterial phyla, though they appear less common outside the two dominant groups.","mcp__togomcp__TogoMCP_Usage_Guide, mcp__pubmed__search_articles, mcp__togomcp__search_uniprot_entity, mcp__ols__search, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch"
question_005,Which human serine/threonine kinase has the most glycosylation sites documented in Glycosmos?,"WNK1 (With No Lysine kinase 1) has the most glycosylation sites among human serine/threonine kinases, with 76 documented sites in Glycosmos - 69% more than the second-ranked kinase FAM20C (45 sites). WNK1 is a master regulator of ion homeostasis controlling renal sodium and potassium transport through phosphorylation of sodium-chloride cotransporters and potassium channels. The extensive glycosylation of WNK1 likely plays critical roles in protein folding, stability, intracellular trafficking, and protein-protein interactions necessary for its regulatory functions. Mutations in WNK1 cause Gordon's syndrome (pseudohypoaldosteronism type II), an autosomal dominant form of hypertension characterized by hyperkalemia and metabolic acidosis, underscoring the clinical importance of proper WNK1 regulation. The exceptional glycosylation extent suggests that WNK1 may be particularly vulnerable to glycosylation defects in congenital disorders of glycosylation, and that glycosylation status could represent a novel regulatory mechanism for modulating WNK1 activity in cardiovascular disease.
",True,"I don't have access to the Glycosmos database or its specific documentation of glycosylation sites on human serine/threonine kinases. Glycosmos is a specialized glycoscience database that catalogs experimentally verified and predicted glycosylation sites, but I cannot query or retrieve information from this external resource. To answer which human serine/threonine kinase has the most documented glycosylation sites in Glycosmos, you would need to directly search the Glycosmos database (https://glycosmos.org) or consult their published datasets. The database allows searches by protein family and glycosylation type, which would enable you to compare glycosylation site numbers across different serine/threonine kinases systematically.",True,"Excellent! Now I have all the information I need to provide a comprehensive answer. Let me provide the final answer as a single, well-formed paragraph:

Human serine/threonine-protein kinase WNK1 (with no lysine 1, UniProt ID Q9H4A3) has the most glycosylation sites documented in Glycosmos, with 76 distinct glycosylation sites. WNK1 functions as a key component of the WNK1-SPAK/OSR1 kinase cascade that regulates blood pressure and cellular volume homeostasis by controlling ion transport across cell membranes. The protein acts as a molecular crowding sensor that responds to hyperosmotic stress by undergoing liquid-liquid phase separation to form membraneless compartments where it can efficiently phosphorylate downstream kinases OXSR1 and SPAK, which in turn regulate Na-K-Cl and K-Cl cotransporters. Beyond its catalytic kinase activity, WNK1 also serves scaffold functions in regulating various membrane transporters and channels, mediates mRNA export through PCF11 phosphorylation, negatively regulates autophagy, and participates in mitotic abscission and actin cytoskeletal reorganization. The second-most glycosylated human serine/threonine kinase in Glycosmos is the extracellular serine/threonine protein kinase FAM20C with 45 glycosylation sites.","mcp__togomcp__TogoMCP_Usage_Guide, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__run_sparql"
